Starzer Angelika M, Preusser Matthias, Berghoff Anna S
Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Division of Oncology, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Ther Adv Med Oncol. 2022 Apr 30;14:17588359221096219. doi: 10.1177/17588359221096219. eCollection 2022.
The introduction of immune checkpoint inhibitors has changed the therapeutic possibilities for various cancer types. However, despite the success in some entities, a significant fraction of patients does not respond to immune checkpoint inhibitors. A functioning cancer-immunity cycle is needed as the precondition for a clinically meaningful response to immune checkpoint inhibitors. It is assumed that only if each step of the cycle is activated and functioning properly, immune checkpoint inhibitors induce a meaningful immune response. However, an activated cancer-immunity cycle might not be present equally in each patient and cancer type. Ideally, treatment concepts should consider each single step of the cancer-immunity cycle and provide personalized treatment approaches, allowing the adaption to functioning and malfunctioning steps of the individual patient's specific cancer-immunity cycle. In the following review, we provide an overview of the single steps of the cancer-immunity cycle as well as the impact of malfunctioning steps on the generation of an effective tumor-specific immune response.
免疫检查点抑制剂的引入改变了多种癌症类型的治疗可能性。然而,尽管在某些实体瘤中取得了成功,但仍有相当一部分患者对免疫检查点抑制剂没有反应。有效的癌症-免疫循环是对免疫检查点抑制剂产生临床有意义反应的前提条件。据推测,只有当循环的每一步都被激活并正常运作时,免疫检查点抑制剂才能诱导有意义的免疫反应。然而,激活的癌症-免疫循环在每个患者和癌症类型中可能并不相同。理想情况下,治疗方案应考虑癌症-免疫循环的每一个步骤,并提供个性化的治疗方法,以适应个体患者特定癌症-免疫循环的正常和异常步骤。在以下综述中,我们概述了癌症-免疫循环的各个步骤,以及异常步骤对有效肿瘤特异性免疫反应产生的影响。